H.C. Wainwright starts Parabilis Medicines at buy
Alpha Vantage · Investing.com Canada · · AI-summarised by FinFlash
H.C. Wainwright initiated coverage on Parabilis Medicines (NASDAQ:PBLS) with a buy rating and a $40.00 price target, implying 44% upside from the $27.85 trading price. The biotechnology company develops cancer therapies on its Helicon platform, holds more cash than debt, and is not expected to be profitable this year.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.